BNTC
Benitec Biopharma Inc.
Price Chart
Latest Quote
$8.69
+0.10 (+1.16%)
Current Price
| Previous Close | $8.59 |
| Open | $8.60 |
| Day High | $8.85 |
| Day Low | $8.52 |
| Volume | 48,646 |
Stock Information
| Shares Outstanding | 34.89M |
| Total Debt | $762K |
| Cash Equivalents | $179.97M |
| Net Income | $-45.55M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $303.19M |
| EPS (TTM) | $-0.98 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $120.43M |
| Income | $-45.55M |
| Book/sh | $5.14 |
| Cash/sh | $5.16 |
| Employees | 24 |
Financial Ratios
| Quick Ratio | 33.68 |
| Current Ratio | 34.00 |
| Debt/Eq | 0.43 |
Returns & Margins
| ROA | -22.67% |
| ROE | -33.21% |
Ownership
| Insider Ownership | 0.24% |
| Institutional Ownership | 96.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.92 |
| P/B | 1.69 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $22.86 |
Technical Indicators
| SMA20 | $8.83 |
| SMA50 | $10.65 |
| SMA200 | $11.59 |
| RSI | 46.23 |
| ATR | 0.5347 |
| Shares Float | 18.49M |
| Short Float | 10.23% |
| Short Ratio | 13.26 |
| Volatility | 0.25 |
| Rel Volume | 0.26 |
Performance History
| Week | -3.87% |
| Month | -13.27% |
| Quarter | -27.88% |
| 6 Months | -28.59% |
| YTD | -30.95% |
| Year | -47.40% |
| 3 Years | +175.00% |
| 5 Years | -86.11% |
| 10 Years | -97.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $8.69 | 48,646 |
| 2026-10-26 | $8.59 | 98,600 |
| 2026-10-23 | $8.65 | 158,400 |
| 2026-10-22 | $8.82 | 149,000 |
| 2026-10-21 | $8.50 | 171,900 |
| 2026-10-20 | $9.04 | 347,600 |
| 2026-10-19 | $8.36 | 194,100 |
| 2026-10-16 | $8.11 | 158,600 |
| 2026-10-15 | $8.46 | 153,700 |
| 2026-10-14 | $8.29 | 162,500 |
| 2026-10-13 | $8.63 | 151,400 |
| 2026-10-12 | $9.07 | 200,900 |
| 2026-10-09 | $8.87 | 73,000 |
| 2026-10-08 | $8.75 | 234,900 |
| 2026-10-07 | $8.99 | 190,100 |
| 2026-10-06 | $9.00 | 217,200 |
| 2026-10-05 | $9.23 | 584,200 |
| 2026-10-02 | $8.98 | 135,100 |
| 2026-10-01 | $9.58 | 103,100 |
| 2026-09-30 | $10.00 | 146,000 |
| 2026-09-29 | $9.75 | 111,000 |
| 2026-09-28 | $10.02 | 152,800 |
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BNTC.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $75,000 |
| Operating Revenue | $0 | $0 | $0 | $75,000 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Total Expenses | $51,192,000 | $41,765,000 | $22,490,000 | $19,156,000 |
| Other Income Expense | $77,000 | $562,000 | $-165,000 | $-448,000 |
| Other Non Operating Income Expenses | $-43,000 | $633,000 | $-204,000 | $-30,000 |
| Net Non Operating Interest Income Expense | $5,569,000 | $3,286,000 | $904,000 | $-33,000 |
| Total Other Finance Cost | $-5,569,000 | $-3,286,000 | $-904,000 | $33,000 |
| Operating Expense | $51,192,000 | $41,765,000 | $22,490,000 | $19,156,000 |
| General And Administrative Expense | $27,804,000 | $23,433,000 | $6,989,000 | $6,382,000 |
| Other Operating Expenses | - | - | $-108,000 | - |
| Interest Expense | - | - | - | $33,000 |
| Interest Expense Non Operating | - | - | - | $33,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Net Interest Income | $5,569,000 | $3,286,000 | $904,000 | $-33,000 |
| Normalized Income | $-45,666,000 | $-37,846,000 | $-21,790,000 | $-19,144,000 |
| Net Income From Continuing And Discontinued Operation | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Total Operating Income As Reported | $-51,192,000 | $-41,765,000 | $-22,490,000 | $-19,081,000 |
| Net Income Common Stockholders | $-45,546,000 | $-37,917,000 | $-22,370,000 | $-19,562,000 |
| Net Income | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Net Income Including Noncontrolling Interests | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Net Income Continuous Operations | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Pretax Income | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Operating Income | $-51,192,000 | $-41,765,000 | $-22,490,000 | $-19,081,000 |
| Special Income Charges | - | $764,000 | $0 | - |
| Gross Profit | - | - | - | $75,000 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.98 | $-1.05 | $-1.22 | $-14.12 |
| Basic EPS | $-0.98 | $-1.05 | $-1.22 | $-14.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-50,831,000 | $-41,298,000 | $-22,186,000 | $-18,282,000 |
| Total Unusual Items | $120,000 | $-71,000 | $39,000 | $-418,000 |
| Total Unusual Items Excluding Goodwill | $120,000 | $-71,000 | $39,000 | $-418,000 |
| Reconciled Depreciation | $481,000 | $396,000 | $343,000 | $381,000 |
| EBITDA (Bullshit earnings) | $-50,711,000 | $-41,369,000 | $-22,147,000 | $-18,700,000 |
| EBIT | $-51,192,000 | $-41,765,000 | $-22,490,000 | $-19,081,000 |
| Diluted Average Shares | $46,558,162 | $36,209,271 | $18,364,386 | $1,385,818 |
| Basic Average Shares | $46,558,162 | $36,209,271 | $18,364,386 | $1,385,818 |
| Diluted NI Availto Com Stockholders | $-45,546,000 | $-37,917,000 | $-22,370,000 | $-19,562,000 |
| Gain On Sale Of Security | $120,000 | $-71,000 | $39,000 | $-418,000 |
| Research And Development | $23,388,000 | $18,332,000 | $15,609,000 | $12,774,000 |
| Selling General And Administration | $27,804,000 | $23,433,000 | $6,989,000 | $6,382,000 |
| Other Gand A | $27,804,000 | $23,433,000 | $6,989,000 | $6,382,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $619,000 | $0 |
| Other Special Charges | - | $-764,000 | - | - |
| Salaries And Wages | - | - | - | $291,000 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Total Assets | $182,623,000 | $99,592,000 | $52,210,000 | $4,464,000 |
| Total Non Current Assets | $938,000 | $1,074,000 | $536,000 | $735,000 |
| Non Current Prepaid Assets | $67,000 | $83,000 | $87,000 | $25,000 |
| Current Assets | $181,685,000 | $98,518,000 | $51,674,000 | $3,729,000 |
| Other Current Assets | $1,595,000 | $628,000 | $516,000 | $1,184,000 |
| Restricted Cash | $114,000 | $113,000 | $63,000 | $13,000 |
| Receivables | $4,000 | $33,000 | $229,000 | $55,000 |
| Accounts Receivable | $4,000 | $33,000 | $229,000 | $55,000 |
| Cash Cash Equivalents And Short Term Investments | $179,972,000 | $97,744,000 | $50,866,000 | $2,477,000 |
| Cash And Cash Equivalents | $179,972,000 | $97,744,000 | $50,866,000 | $2,477,000 |
| Cash Financial | $179,972,000 | $97,744,000 | $50,866,000 | $2,477,000 |
| Other Non Current Assets | - | - | $62,000 | $97,000 |
| Prepaid Assets | - | - | - | - |
| Cash Equivalents | - | - | - | - |
| Debt | ||||
| Total Debt | $762,000 | $849,000 | $284,000 | $559,000 |
| Long Term Debt And Capital Lease Obligation | $266,000 | $495,000 | $0 | $284,000 |
| Current Debt And Capital Lease Obligation | $496,000 | $354,000 | $284,000 | $275,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,610,000 | $2,297,000 | $4,962,000 | $4,262,000 |
| Total Non Current Liabilities Net Minority Interest | $266,000 | $495,000 | $38,000 | $284,000 |
| Current Liabilities | $5,344,000 | $1,802,000 | $4,924,000 | $3,978,000 |
| Payables And Accrued Expenses | $4,295,000 | $1,022,000 | $4,165,000 | $3,231,000 |
| Payables | $1,764,000 | $268,000 | $1,489,000 | $1,209,000 |
| Other Payable | $851,000 | $67,000 | $138,000 | $69,000 |
| Accounts Payable | $913,000 | $201,000 | $1,351,000 | $1,140,000 |
| Equity | ||||
| Common Stock Equity | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Total Equity Gross Minority Interest | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Stockholders Equity | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Gains Losses Not Affecting Retained Earnings | $-963,000 | $-839,000 | $-892,000 | $-830,000 |
| Other Equity Adjustments | $-963,000 | $-839,000 | $-892,000 | $-830,000 |
| Retained Earnings | $-273,722,000 | $-228,176,000 | $-190,259,000 | $-167,889,000 |
| Other | ||||
| Ordinary Shares Number | $34,416,834 | $26,250,469 | $10,086,119 | $1,645,950 |
| Share Issued | $34,416,834 | $26,250,469 | $10,086,119 | $1,645,950 |
| Tangible Book Value | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Invested Capital | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Working Capital | $176,341,000 | $96,716,000 | $46,750,000 | $-249,000 |
| Capital Lease Obligations | $762,000 | $849,000 | $284,000 | $559,000 |
| Total Capitalization | $177,013,000 | $97,295,000 | $47,248,000 | $202,000 |
| Additional Paid In Capital | $451,695,000 | $326,308,000 | $238,398,000 | $168,921,000 |
| Capital Stock | $3,000 | $2,000 | $1,000 | $0 |
| Common Stock | $3,000 | $2,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $266,000 | $495,000 | $0 | $284,000 |
| Current Capital Lease Obligation | $496,000 | $354,000 | $284,000 | $275,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $553,000 | $426,000 | $475,000 | $472,000 |
| Current Accrued Expenses | $2,531,000 | $754,000 | $2,676,000 | $2,022,000 |
| Net PPE | $871,000 | $991,000 | $449,000 | $613,000 |
| Accumulated Depreciation | $-1,316,000 | $-1,470,000 | $-1,404,000 | $-1,318,000 |
| Gross PPE | $2,187,000 | $2,461,000 | $1,853,000 | $1,931,000 |
| Leases | $22,000 | $24,000 | $24,000 | $24,000 |
| Other Properties | $1,390,000 | $1,533,000 | $1,521,000 | $1,343,000 |
| Machinery Furniture Equipment | $82,000 | $44,000 | $38,000 | $38,000 |
| Buildings And Improvements | $693,000 | $860,000 | $270,000 | $526,000 |
| Properties | $0 | $0 | $0 | $0 |
| Employee Benefits | - | $0 | $38,000 | - |
| Long Term Provisions | - | - | $38,000 | - |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,623,000 | $-23,606,000 | $-19,582,000 | $-18,013,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,518,000 | $-23,588,000 | $-19,403,000 | $-18,012,000 |
| Cash Flow From Continuing Operating Activities | $-16,518,000 | $-23,588,000 | $-19,403,000 | $-18,012,000 |
| Investing Activities | ||||
| Capital Expenditure | $-105,000 | $-18,000 | $-179,000 | $-1,000 |
| Investing Cash Flow | $-105,000 | $-18,000 | $-179,000 | $-1,000 |
| Cash Flow From Continuing Investing Activities | $-105,000 | $-18,000 | $-179,000 | $-1,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $104,495,000 | $30,460,000 | $70,883,000 | $17,884,000 |
| Financing Cash Flow | $98,977,000 | $70,485,000 | $68,029,000 | $16,015,000 |
| Cash Flow From Continuing Financing Activities | $98,977,000 | $70,485,000 | $68,029,000 | $16,015,000 |
| Net Other Financing Charges | $-6,266,000 | $-2,319,000 | $-5,892,000 | $-1,869,000 |
| Net Common Stock Issuance | $104,495,000 | $30,460,000 | $70,883,000 | $17,884,000 |
| Common Stock Issuance | $104,495,000 | $30,460,000 | $70,883,000 | $17,884,000 |
| Other | ||||
| End Cash Position | $180,086,000 | $97,857,000 | $50,929,000 | $2,490,000 |
| Beginning Cash Position | $97,857,000 | $50,929,000 | $2,490,000 | $4,076,000 |
| Effect Of Exchange Rate Changes | $-125,000 | $49,000 | $-8,000 | $412,000 |
| Changes In Cash | $82,354,000 | $46,879,000 | $48,447,000 | $-1,998,000 |
| Proceeds From Stock Option Exercised | $748,000 | $42,344,000 | $3,038,000 | - |
| Net PPE Purchase And Sale | $-105,000 | $-18,000 | $-179,000 | $-1,000 |
| Purchase Of PPE | $-105,000 | $-18,000 | $-179,000 | $-1,000 |
| Change In Working Capital | $2,137,000 | $-2,729,000 | $1,174,000 | $714,000 |
| Change In Other Current Liabilities | $-343,000 | $-356,000 | $-275,000 | $-252,000 |
| Change In Payables And Accrued Expense | $3,398,000 | $-2,459,000 | $980,000 | $1,430,000 |
| Change In Accrued Expense | $126,000 | $-81,000 | $39,000 | $73,000 |
| Change In Payable | $3,272,000 | $-2,378,000 | $941,000 | $1,357,000 |
| Change In Prepaid Assets | $-948,000 | $-111,000 | $645,000 | $-414,000 |
| Change In Receivables | $30,000 | $197,000 | $-176,000 | $-50,000 |
| Stock Based Compensation | $26,410,000 | $17,426,000 | $830,000 | $452,000 |
| Depreciation Amortization Depletion | $481,000 | $396,000 | $343,000 | $381,000 |
| Depreciation And Amortization | $481,000 | $396,000 | $343,000 | $381,000 |
| Depreciation | $481,000 | $396,000 | $343,000 | $381,000 |
| Net Income From Continuing Operations | $-45,546,000 | $-37,917,000 | $-21,751,000 | $-19,562,000 |
| Other Non Cash Items | - | $-764,000 | - | - |
| Unrealized Gain Loss On Investment Securities | - | $0 | $1,000 | $3,000 |
| Change In Other Working Capital | - | - | - | $73,000 |
| Sale Of PPE | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-10-25